SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 3/23/2017 2:39:03 PM - Followers: 12 - Board type: Free - Posts Today: 0



Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.


 PDF Presentation Feb 2011:



Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011



Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

AOLS (Daily)

AOLS (Weekly)


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AOLS News: Current Report Filing (8-k) 03/24/2017 11:51:26 AM
AOLS News: Quarterly Report (10-q) 02/17/2017 04:04:16 PM
AOLS News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 02/14/2017 11:17:47 AM
AOLS News: Amended Annual Report (10-k/a) 01/30/2017 05:06:26 PM
AOLS News: Statement of Changes in Beneficial Ownership (4) 12/30/2016 04:55:45 PM
#370  Sticky Note Been a stockholder for AOLS about six years. fishhawk127 03/19/17 09:42:03 AM
#385   Someone took a nice chunk out of that Rogue Dead Guy 03/23/17 02:39:03 PM
#384   That 85k on .09 needs to be taken Rogue Dead Guy 03/23/17 02:30:37 PM
#383   A break back into that .1-.15 range would Rogue Dead Guy 03/23/17 12:38:06 PM
#382   Interesting day here... $AOLS Rogue Dead Guy 03/23/17 11:36:30 AM
#381   I just have to think there must be Sheep 03/23/17 11:13:21 AM
#380   150k slappage and we should be green! $AOLS Rogue Dead Guy 03/23/17 11:11:45 AM
#379   Indeed it is! $AOLS Rogue Dead Guy 03/23/17 11:10:08 AM
#378   The question is: what can management do to GetSeriousOK 03/23/17 11:07:32 AM
#377   Areola getting pinched today. willlbone 03/23/17 10:33:26 AM
#376   Still bullish? GetSeriousOK 03/23/17 10:12:17 AM
#375   Wow not the news we were looking for. Sheep 03/23/17 08:44:05 AM
#374   AOLS News: Quarterly Report (10-q) 02/17/2017 04:04:16 PM mick 03/22/17 01:46:30 PM
#373   Aeolus Pharmaceutica (AOLS) mick 03/22/17 01:46:08 PM
#372   Thanks to the user who sent me a Sheep 03/20/17 10:33:51 AM
#371   If I were still a paying member of Sheep 03/19/17 12:41:37 PM
#370   Been a stockholder for AOLS about six years. fishhawk127 03/19/17 09:42:03 AM
#369   I wish I was holding more at this Sheep 03/17/17 12:42:38 PM
#368   It's about time this started trading higher. Although, Zlinger 03/17/17 12:26:03 PM
#367   This stock is so undervalued it is not Sheep 03/17/17 12:13:49 PM
#366   PR Today: Sheep 03/15/17 10:15:06 AM
#365   I think we are headed back to the Sheep 03/14/17 01:47:51 PM
#364   Thank I had not seen that. Here is Sheep 03/06/17 12:05:05 PM
#363   New study published: Falco 03/04/17 06:51:19 AM
#362   Phase 1 on healthy patients to being soon. Sheep 02/22/17 09:50:37 AM
#361   AOLS News: Amended Annual Report (10-k/a) 01/30/2017 05:06:26 PM mick 02/12/17 06:50:44 PM
#360   Aeolus Pharmaceutica (AOLS) mick 02/12/17 06:50:38 PM
#359   I agree. I think 2017 is the year. Sheep 01/27/17 09:05:40 AM
#358   Hoping that 2017 is the year here. Should Falco 01/26/17 07:11:10 AM
#357   Aeolus Pharmaceutica (AOLS) mick 12/26/16 11:56:04 PM
#356   AOLS News: Securities Registration Statement (s-1) 12/20/2016 05:28:18 PM mick 12/26/16 11:55:51 PM
#355   Aeolus Pharmaceutica (AOLS) mick 12/04/16 10:25:26 PM
#354   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 12/04/16 10:25:05 PM
#353   Aeolus Pharmaceutica (AOLS) mick 10/29/16 03:25:42 PM
#352   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 10/13/16 11:49:19 PM
#351   Aeolus Pharmaceutica (AOLS) mick 10/13/16 11:49:14 PM
#350   If you have not looked at the latest Sheep 10/04/16 09:11:02 AM
#349   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 10/01/16 09:23:14 AM
#348   Aeolus Pharmaceutica (AOLS) mick 10/01/16 09:23:08 AM
#347   I am still holding this. It is just Sheep 09/29/16 10:11:16 AM
#346   Noted. Huge buy 250K bid vs small avail ABNormal 09/27/16 07:04:08 PM
#345   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 09/18/16 12:02:53 PM
#344   Aeolus Pharmaceutica (AOLS) mick 09/18/16 12:02:48 PM
#343   Great news: Sheep 09/06/16 01:14:34 PM
#342   AOLS News: Quarterly Report (10-q) 08/15/2016 04:15:53 PM mick 09/03/16 04:03:34 PM
#341   Aeolus Pharmaceutica (AOLS) mick 09/03/16 04:03:12 PM
#340   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 08/13/16 05:23:44 PM
#339   Aeolus Pharmaceutica (AOLS) mick 08/13/16 05:23:30 PM
#338   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 07/23/16 10:53:16 PM
#337   Aeolus Pharmaceutica (AOLS) mick 07/23/16 10:53:11 PM
#336   THANK YOU, mick 07/10/16 11:52:06 AM